With the publication of numbers of trials and clinical studies on Kanglaite injection forGC, there is an urgent need for a systematic review to assess the effectiveness and safety of Kanglaite injection in treating GC. Researches showed that Kanglaite injection could effectively reverse multiple-drug resistance in cancer cells and enhance the sensitivity of tumor cells to chemotherapeutic drugs. It has been widely used for the treatment of Pancreatic cancer, lung cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, and GC. Millions cancer patients in more than 2000 hospitals in China have been treated with Kanglaite injection. It is also the first Chinese medicine approved by the US Food and Drug Administration, and has been used as a biphasic broad-spectrum antitumor drug in clinical trials in the United States.
In 1995, Kanglaite injection, which is extracted from the seeds of the Chinese medicinal herb Coix lacryma-jobi, was approved by the State Food and Drug Administration of China (Drug Approval Number: Z10970091) for the treatment of various cancers. In recent years, Coix seed and its extracts have been used to treat many diseases such as cancer, arthritis, hypertension, asthma, and immunological disorders. As one of famous Chinese herb, Coix seed is well known for its anti-tumor and immunomodulatory effects. Various natural products from Chinese herbal extracts exhibit strong inhibitory properties against carcinogenesis. Traditional Chinese medicine has been used for thousands of years and is widely used as an alternative or combined treatment for cancers.
Thus, implementation of a multimodality treatment approach is of great significance to further improve survival. With high incidence and mortality rate, GC causes a serious health burden globally, especially in several Western Asian and Eastern Asia countries (eg, in Mongolia, Japan, and the Republic of Korea). Despite recent advances in therapeutic methods including surgery combined with chemotherapy and radiotherapy, the prognosis for advanced GC patients remains very poor. Gastric cancer (GC) is the fifth most frequently diagnosed cancer and the third leading cause of cancer death, which was responsible for over 1,000,000 new cases in 2018 and an estimated 783,000 deaths.
0 kommentar(er)
